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One century after its discovery vitamin D is shown to
be, in fact, a pleiotropic steroid hormone which, beside
regulation of calcium homeostasis and bone turnover,
has anti-proliferative, pro-differentiation, anti-bacterial,
immunomodulatory and anti-inflammatory properties in
various cells and tissues.
The D hormone [1a,25(OH)2D], regulated in endo-
crine, autocrine and paracrine manner, must be bound
to the specific nuclear vitamin D receptor (VDR) to
exert epigenetic and genetic effects influencing more
than 2000 genes in all tissues and immune cells, essen-
tial for proliferation, differentiation and immunoregula-
tion. VDR agonists inhibit in myeloid DCs, but not in
plazmacytoid DCs, expression of surface co-stimulatory
molecules such as MHC class II, CD40, CD80 and
CD86. In T cells, 1,25(OH)2D decreases the production
of IL-2, IL-17 and interferon-g (IFNg) and attenuates the
cytotoxic activity and proliferation of CD4+ and CD8+
T cells, and promote the development of FoxP3+ regula-
tory T (TReg) cells and IL-10-producing T regulatory
type 1 cells. In contrast to glucocorticoids which are
non-selective immunosuppressive compaunds, 1a,25(OH)
2D induces monocyte proliferation and the expression of
interleukin-1 (IL-1) and cathelicidin (an antimicrobial
peptide) by macrophages, thereby contributing to innate
immune responses to some bacteria. Additionally it was
shown that 1a,25(OH)2D can override steroid resistance
and antagonize its negative bone turnover influence.
The discovery of the immunomodulatory and anti-
tumor properties of D-hormone prompted researchers
to investigate possibility of its use as a preventive and
therapeutic agent for different autoimmune and malig-
nant diseases. Several publications in last years have
found a high prevalence of vitamin D deficiency in JIA,
SLE and other chronic inflammatory diseases in
childhood, with the mean values of 25(OH)D levels at
the lower end of ‘acceptable’ range. Measurement of
25(OH)D level (as the only standardized toll to estimate
vitamin D status) is actually only the reflection of the
balance between food and/or supplement vitamin D diet
intake and its utilization in the local tissues into the
active D hormone (especially immune cells in the state
of chronic inflammation). Recent recommendations and
clinical guidelines have suggested vitamin D supplemen-
tation of up to 2000 IU/d to be safe and well tolerated
in children with chronic diseases.
New recommendations and guidelines for vitamin
D supplementation, as adjunct treatment option in JIA
and other chronic inflammatory rheumatic diseases, is an
appealing need due to its pleiotropic effects. It can both
minimize bone fragility and contribute improvement of
impaired immunity regulation in rheumatic diseases in
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